Meeting Objectives:
• Discuss the need to consider other treatment targets beyond just glucose and understand why it’s
important to effectively manage weigh, cardiometabolic targets, etc.
• Acknowledge the problem of therapeutic inertia and the long-term benefits of an early intensive
intervention for T2D.
• Debate how scientific evidence support possible “legacy effect”; what impact will have on current position
of medicines in guideline and future evolution; what implications can be expected on a clinical practice
and patient outcome perspective.
Meeting Objectives:
• Discuss the need to consider other treatment targets beyond just glucose and understand why it’s
important to effectively manage weigh, cardiometabolic targets, etc.
• Acknowledge the problem of therapeutic inertia and the long-term benefits of an early intensive
intervention for T2D.
• Debate how scientific evidence support possible “legacy effect”; what impact will have on current position
of medicines in guideline and future evolution; what implications can be expected on a clinical practice
and patient outcome perspective.
FREE
Free